Mats Enlund

Tim Hale

The primary objective of his latest clinical trial is to evaluate whether the one- and five-year survival after radical breast-, or colorectal cancer surgery with general anaesthesia is significantly higher in patients given propofol than in patients given sevoflurane. The difference is seen as significantly higher and clinically relevant if the absolute difference in five-year-survival is minimum 5%-units. Animal data, laboratory studies, and two retrospective patient studies indicate that propofol may be advantageous.

Back to Members